Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2

Status

Completed 3Terminated 2

Sponsor Class

OTHER 12INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Neoplasms 3Cancer Pain 3Substance Withdrawal Syndrome 1Pain 1Chronic Pain 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Morphine × Clear all
NCT00505414 2019-11-01

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Terminated
136 enrolled 9 charts

Neoplasms, Pain

NCT02660229 2018-11-19

SWITCH

Mundipharma Korea Ltd

Phase 4 Completed
66 enrolled 10 charts

Cancer Pain

NCT01675622 2018-05-21

Immediate-Release Oxycodone Capsules Study in Cancer Pain

Mundipharma (China) Pharmaceutical Co. Ltd

Phase 3 Completed
242 enrolled 20 charts

Cancer Pain, Neoplasms

NCT01309386 2013-03-13

A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants

Janssen Pharmaceutical K.K.

Phase 3 Completed
100 enrolled 12 charts

Cancer Pain, Neoplasms

NCT01100437 2012-07-13

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

Pfizer

Phase 4 Terminated
14 enrolled 18 charts

Substance Withdrawal Syndrome, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡